ThinkEquity Downgrades Nektar Therapeutics (NKTR) to Sell, Reaffirms $5 Price Target
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $73.02 -3.82%
Rating Summary:
20 Buy, 7 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
20 Buy, 7 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
ThinkEquity downgraded shares of Nektar Therapeutics (NASDAQ: NKTR) to a Sell rating from its previous rating of Hold. The firm reaffirmed its price target of $5.00.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $6.72 yesterday.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $6.72 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
- Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
